Close Menu

NEW YORK (GenomeWeb) – Thermo Fisher Scientific said after the close of the market Friday that it is acquiring Affymetrix for approximately $1.3 billion.

The firms said in a joint statement that the boards of directors of both firms have unanimously approved Thermo Fisher's offer to acquire Affymetrix for $14 per share, a 52 percent premium to Affy's closing price of $9.21 on Friday.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new blood test might be able to detect the presence of some 50 cancers, according to New Scientist.

Undark looks into how coronavirus-related shutdowns are affecting field researchers.

In PNAS this week: strategies to design DNA oligonucleotide probes for bacteria, Vibrio cholerae evolution in Haiti, and more.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.